Based on the pharmacodynamics of SGLT2 inhibitors and the pathophysiology of cognitive diseases, this review also demonstrated the synergistic potential of SGLT2 inhibitors and suggested future research avenues. This evidence concerns the gene SLC5A2 and cognitive disorder.